A detailed history of Perfromance Wealth Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Perfromance Wealth Partners, LLC holds 1,603 shares of VRTX stock, worth $754,003. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,603
Previous 1,616 0.8%
Holding current value
$754,003
Previous $751,000 14.11%
% of portfolio
0.02%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 17, 2025

SELL
$396.64 - $516.74 $5,156 - $6,717
-13 Reduced 0.8%
1,603 $645,000
Q3 2024

Oct 10, 2024

BUY
$460.0 - $505.78 $7,360 - $8,092
16 Added 1.0%
1,616 $751,000
Q2 2023

Jul 13, 2023

BUY
$314.42 - $351.91 $125,768 - $140,764
400 Added 33.33%
1,600 $563,000
Q1 2023

Apr 20, 2023

BUY
$283.23 - $323.1 $113,292 - $129,240
400 Added 50.0%
1,200 $378,000
Q4 2022

Jan 19, 2023

BUY
$285.76 - $321.48 $228,608 - $257,184
800 New
800 $0

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Perfromance Wealth Partners, LLC Portfolio

Follow Perfromance Wealth Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perfromance Wealth Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perfromance Wealth Partners, LLC with notifications on news.